Excess visceral fat is associated with chronic systemic inflammation and cardiovascular
complications. Pioglitazone has been reported to variably influence visceral fat volume, but
it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate
the effect of pioglitazone on glucose metabolism of fat tissue by using
18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
imaging.